Sinjini Sarkar1,2, Pranab K Sahoo1, Ranita Pal1, Tanuma Mistry1, Sutapa Mahata1, Puja Chatterjee3, Manisha Vernekar3, Syamsundar Mandal4, Tanmoy Bera2, Vilas D Nasare5. 1. Department of Pathology and Cancer Screening, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, 700026, India. 2. Department of Pharmaceutical Technology, Jadavpur University, 188, Raja S. C. Mallick Rd, Kolkata, 700032, India. 3. Department of Gynaecological Oncology, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, 700026, India. 4. Department of Epidemiology and Biostatistics, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, 700026, India. 5. Department of Pathology and Cancer Screening, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, 700026, India. vilas.dr@gmail.com.
Abstract
PURPOSE: The study aims to record the quality of life (Qol) and its changes while ovarian cancer (OC) patients undergo debulking surgeries and chemotherapy in a tertiary care hospital of Eastern India. METHODS: Patients with advanced epithelial OC (FIGO stages III-IV) were recruited. They underwent primary/interval debulking surgeries with classical chemotherapy (adjuvant/neoadjuvant) of intravenous tri-weekly doses of paclitaxel + carboplatin. QoL was assessed using Fact- O + FACIT-Sp-12 questionnaire with a set of 51 questions in different domains (spiritual, physical, social, emotional, and functional factors) and a special set for OC patients under the heading "Additional concerns." The responses from patients were recorded at baseline (diagnosis/study entry), 2, 4, and 6 months during the treatment visits. Overall survival (OS) was assessed using Kaplan Meier curve. RESULTS: A majority of patients were 49.15±10.8 years of age, school-educated (54%), unemployed/homemakers (73.5%), belonging from rural setup (64.6%) with a monthly income of Rs. 2000/- to Rs. 5000/-. There was no statistically significant (p>0.05) improvement found in Qol from the baseline till the end of the study, neither overall nor in subsets (responders (Rs)/partial responders (PRs)/non-responder (NRs) groups or the adjuvant and neoadjuvant chemotherapy groups). The common toxicities like anemia, constipation, and weight loss were significantly (p<0.05) correlated with the patients' physical, functional, emotional, and social well-being. CONCLUSION: Ovarian cancer patients represent a poor functional, social, and disease-specific quality of life that needs to be addressed, identified, and improved by the growing nexus of healthcare providers and researchers.
PURPOSE: The study aims to record the quality of life (Qol) and its changes while ovarian cancer (OC) patients undergo debulking surgeries and chemotherapy in a tertiary care hospital of Eastern India. METHODS: Patients with advanced epithelial OC (FIGO stages III-IV) were recruited. They underwent primary/interval debulking surgeries with classical chemotherapy (adjuvant/neoadjuvant) of intravenous tri-weekly doses of paclitaxel + carboplatin. QoL was assessed using Fact- O + FACIT-Sp-12 questionnaire with a set of 51 questions in different domains (spiritual, physical, social, emotional, and functional factors) and a special set for OC patients under the heading "Additional concerns." The responses from patients were recorded at baseline (diagnosis/study entry), 2, 4, and 6 months during the treatment visits. Overall survival (OS) was assessed using Kaplan Meier curve. RESULTS: A majority of patients were 49.15±10.8 years of age, school-educated (54%), unemployed/homemakers (73.5%), belonging from rural setup (64.6%) with a monthly income of Rs. 2000/- to Rs. 5000/-. There was no statistically significant (p>0.05) improvement found in Qol from the baseline till the end of the study, neither overall nor in subsets (responders (Rs)/partial responders (PRs)/non-responder (NRs) groups or the adjuvant and neoadjuvant chemotherapy groups). The common toxicities like anemia, constipation, and weight loss were significantly (p<0.05) correlated with the patients' physical, functional, emotional, and social well-being. CONCLUSION: Ovarian cancer patients represent a poor functional, social, and disease-specific quality of life that needs to be addressed, identified, and improved by the growing nexus of healthcare providers and researchers.
Authors: Lauren Z Davis; Michaela Cuneo; Premal H Thaker; Michael J Goodheart; David Bender; Susan K Lutgendorf Journal: Psychooncology Date: 2017-08-04 Impact factor: 3.894
Authors: F Joly; D Ahmed-Lecheheb; E Kalbacher; N Heutte; B Clarisse; J M Grellard; F Gernier; D Berton-Rigaud; O Tredan; M Fabbro; A M Savoye; J E Kurtz; J Alexandre; P Follana; V Delecroix; N Dohollou; C Roemer-Becuwe; G De Rauglaudre; A Lortholary; K Prulhiere; A Lesoin; A Zannetti; S N'Guyen; S Trager-Maury; L Chauvenet; S Abadie Lacourtoisie; A Gompel; C Lhommé; A Floquet; P Pautier Journal: Ann Oncol Date: 2019-05-01 Impact factor: 32.976
Authors: K Basen-Engquist; D Bodurka-Bevers; M A Fitzgerald; K Webster; D Cella; S Hu; D M Gershenson Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Michael Friedlander; Val Gebski; Emma Gibbs; Lucy Davies; Ralph Bloomfield; Felix Hilpert; Lari B Wenzel; Daniel Eek; Manuel Rodrigues; Andrew Clamp; Richard T Penson; Diane Provencher; Jacob Korach; Tomasz Huzarski; Laura Vidal; Vanda Salutari; Clare Scott; Maria Ornella Nicoletto; Kenji Tamura; David Espinoza; Florence Joly; Eric Pujade-Lauraine Journal: Lancet Oncol Date: 2018-07-17 Impact factor: 41.316